VIVUS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | $16.1M | $11.9M | $65.4M | $124.3M | $95.4M | $114.2M |
| Operating income | −$11.0M | −$3.5M | $2.8M | $55.7M | −$60.3M | −$50.7M |
| Net income | −$31.5M | −$37.0M | −$30.5M | $23.3M | −$93.1M | −$82.6M |
| Total assets | $218.3M | $302.1M | $265.0M | $305.8M | $277.2M | $366.9M |
| Total liabilities | $287.5M | $342.2M | $274.3M | $287.6M | $284.3M | $284.4M |
| Equity | −$69.2M | −$40.0M | −$9.3M | $18.2M | −$7.1M | $82.5M |
| EPS (diluted) | — | $-3.48 | $-2.89 | $2.22 | $-0.90 | $-0.80 |
| Shares out. | 10.6M | 106.0M | 105.6M | 104.1M | 103.9M | 103.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- −67.9%
- Net margin
- −195.1%
- Return on equity
- 45.5%
- Return on assets
- −14.4%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 131.7%
- Debt / equity
- —
- Book value / share
- $-6.51
- Revenue growth (YoY)
- 35.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- -18.07distress
- Accruals / assets
- −0.5%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 17, 2020
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Recruitingreadout ~2027-03-31A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
- Phase 3Not Yet Recruitingreadout ~2028-05-31A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Other material eventNov 16, 2020
- Delisting / listing-standard notice · Regulation FD disclosureJul 13, 2020
- Entered a material agreement · Bankruptcy or receivership · Debt acceleration / triggering event · Director / officer change · Regulation FD disclosureJul 7, 2020
- Regulation FD disclosureJun 19, 2020
- Entered a material agreement · Regulation FD disclosureJun 2, 2020
- Results of operationsMay 8, 2020
- Results of operationsMay 6, 2020
- Entered a material agreement · Debt acceleration / triggering event · Regulation FD disclosure · Other material eventMay 1, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12BJan 8, 2021
- SC 13G/ASABBY 13G-A VVUS 1.05.21Jan 5, 2021
- EFFECTDec 30, 2020
- EFFECTDec 30, 2020
- S-8 POSDec 30, 2020
- S-8 POSDec 30, 2020
- S-8 POSDec 30, 2020
- S-8 POSDec 30, 2020
- S-8 POSDec 30, 2020
- S-8 POSDec 30, 2020
- S-8 POSDec 30, 2020
- S-8 POSDec 30, 2020
- S-8 POSDec 30, 2020
- S-8 POSDec 30, 2020
- S-8 POSDec 30, 2020
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.